Table 5 Societal and 3rd party insurer cost perspective cost-utility analyses (2015 U.S. real dollars discounted at 3% annually)

Ranibizumab therapy, direct ocular medical costs^a

79,056

79,056

Depression^b

(2543)

(2543)

Injury^b

(664)

(664)

Subacute Nursing Facility (SNF)^b

(4100)

(4100)

Nursing home^b

(19,046)

(19,046)

Unexplained direct medical Medicare costs^b

(28,598)

(28,598)

Patient employment gain^a

(9057)

–

Paid caregivers released from jobs^b

(82,419)

–

Increased paid employment by freed-up unpaid caregivers^a

(215,123)

–

Total costs offsetting the direct ophthalmic medical costs

(361,573)

(54,974)

Direct medical costs + offsetting costs = financial return to society

282,517

(24,082)

Financial ROI for direct ophthalmic medical costs expended

14.7%

−3.5%

QALY gain: combined-eye model

1.136

1.136

QALY gain: second-eye model

1.372

1.372

VRQOL gain, combined-eye model

16.3%

16.3%

VRQOL gain, second-eye model

22.8%

22.8%

$/QALY, combined-eye model

(242,921)

20,707

$/QALY, second-eye model

(205,916)

17,552

Addition to GDP

165,842

24,082

Financial ROI for GDP referent to direct ophthalmic medical costs expended

7.0%

−11.4%